Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.


Aventis Effort Explaining Deep-Vein Thrombosis Linked to Drug Lovenox

By Published on .

NEW YORK (AdAge.com) -- Drug maker Aventis has selected three agencies within WPP Group's Young & Rubicam network to handle an awareness campaign for a condition known as deep-vein thrombosis.

Aventis manufactures Lovenox, a drug frequently prescribed to treat deep-vein thrombosis.

Y&R Advertising, public relations agency Burson-Marsteller and Mediaedge:CIA, for media buying, all New York, are charged with creating a campaign explaining deep-vein thrombosis, a condition that most often is a blood clot in the deep veins of the leg that may lead to pulmonary embolism.

An Aventis spokeswoman confirmed that the company conducted a review, in which agencies from holding companies including WPP, Omnicom Group and Interpublic Group of Cos., participated, though she declined to discuss specific competitors.

Spending on the account has not been determined. The drug maker in July launched a Web site, www.thrombosisonline.com, to disseminate information on the condition.

Most Popular